Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells

Science Signaling

Volumn 6, Issue 260, 2013, Pages

  Beck, Daniela ^a   Niessner, Heike ^a   Smalley, Keiran S M ^b   Flaherty, Keith ^c   Paraiso, Kim H T ^b   Busch, Christian ^a   Sinnberg, Tobias ^a   Vasseur, Sophie ^d,e,f,g   Iovanna, Juan Lucio ^d   Drießen, Stefan ^h   Stork, Björn ^h   Wesselborg, Sebastian ^h   Schaller, Martin ^a   Biedermann, Tilo ^a   Bauer, Jürgen ^a   Lasithiotakis, Konstantinos ^a   Weide, Benjamin ^a   Eberle, Jürgen ⁱ   Schittek, Birgit ^a   Schadendorf, Dirk ^j   Garbe, Claus ^a   Kulms, Dagmar ^k,l   Meier, Friedegund ^a   more..

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d INSERM   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g CNRS   (France)

^h UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF DUISBURG ESSEN   (Germany)

^k UNIVERSITY OF STUTTGART   (Germany)

^l DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; B RAF KINASE; CHAPERONE; GLUCOSEREGULATED PROTEIN 78; INITIATION FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; THAPSIGARGIN; UNCLASSIFIED DRUG; VEMURAFENIB; X BOX BINDING PROTEIN 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; DRUG POTENCY; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENE MUTATION; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ACTIVATING TRANSCRIPTION FACTOR 4; AMINO ACID SUBSTITUTION; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CHICK EMBRYO; DNA-BINDING PROTEINS; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; MALE; MELANOMA; MUTATION, MISSENSE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TRANSCRIPTION FACTORS;

EID: 84873399856     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003057     Document Type: Article

References (47)

1. C. M. Balch, J. E. Gershenwald, S. J. Soong, J. F. Thompson, M. B. Atkins, D. R. Byrd, A. C. Buzaid, A. J. Cochran, D. G. Coit, S. Ding, A. M. Eggermont, K. T. Flaherty, P. A. Gimotty, J. M. Kirkwood, K. M. McMasters, M. C. Mihm Jr., D. L. Morton, M. I. Ross, A. J. Sober, V. K. Sondak, Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206 (2009).
2. H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M. J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B. A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G. J. Riggins, D. D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J. W. Ho, S. Y. Leung, S. T. Yuen, B. L. Weber, H. F. Seigler, T. L. Darrow, H. Paterson, R. Marais, C. J. Marshall, R. Wooster, M. R. Stratton, P. A. Futreal, Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
3. K. Satyamoorthy, G. Li, M. R. Gerrero, M. S. Brose, P. Volpe, B. L. Weber, P. Van Belle, D. E. Elder, M. Herlyn, Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer. Res. 63, 756-759 (2003).
4. D. L. Dai, M. Martinka, G. Li, Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J. Clin. Oncol. 23, 1473-1482 (2005).
5. F. Meier, B. Schittek, S. Busch, C. Garbe, K. Smalley, K. Satyamoorthy, G. Li, M. Herlyn, The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. 10, 2986-3001 (2005).
6. J. A. Sosman, K. B. Kim, L. Schuchter, R. Gonzalez, A. C. Pavlick, J. S. Weber, G. A. McArthur, T. E. Hutson, S. J. Moschos, K. T. Flaherty, P. Hersey, R. Kefford, D. Lawrence, I. Puzanov, K. D. Lewis, R. K. Amaravadi, B. Chmielowski, H. J. Lawrence, Y. Shyr, F. Ye, J. Li, K. B. Nolop, R. J. Lee, A. K. Joe, A. Ribas, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714 (2012).
7. P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S. J. O'Day, J. A. Sosman, J. M. Kirkwood, A. M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R. J. Lee, K. T. Flaherty, G. A. McArthur; BRIM-3 Study Group, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
8. K. T. Flaherty, I. Puzanov, K. B. Kim, A. Ribas, G. A. McArthur, J. A. Sosman, P. J. O'Dwyer, R. J. Lee, J. F. Grippo, K. Nolop, P. B. Chapman, Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
9. H. Shi, G. Moriceau, X. Kong, M. K. Lee, H. Lee, R. C. Koya, C. Ng, T. Chodon, R. A. Scolyer, K. B. Dahlman, J. A. Sosman, R. F. Kefford, G. V. Long, S. F. Nelson, A. Ribas, R. S. Lo, Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724 (2012).
10. P. I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, G. Moriceau, H. Shi, M. Atefi, B. Titz, M. T. Gabay, M. Salton, K. B. Dahlman, M. Tadi, J. A.Wargo, K. T. Flaherty, M. C. Kelley, T. Misteli, P. B. Chapman, J. A. Sosman, T. G. Graeber, A. Ribas, R. S. Lo, N. Rosen, D. B. Solit, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
11. P. I. Poulikakos, N. Rosen, Mutant BRAF melanomas-Dependence and resistance. Cancer Cell 19, 11-15 (2011).
12. N. Wagle, C. Emery, M. F. Berger, M. J. Davis, A. Sawyer, P. Pochanard, S. M. Kehoe, C. M. Johannessen, L. E. MacConaill, W. C. Hahn, M. Meyerson, L. A. Garraway, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096 (2011).
13. C. M. Johannessen, J. S. Boehm, S. Y. Kim, S. R. Thomas, L. Wardwell, L. A. Johnson, C. M. Emery, N. Stransky, A. P. Cogdill, J. Barretina, G. Caponigro, H. Hieronymus, R. R. Murray, K. Salehi-Ashtiani, D. E. Hill, M. Vidal, J. J. Zhao, X. Yang, O. Alkan, S. Kim, J. L. Harris, C. J. Wilson, V. E. Myer, P. M. Finan, D. E. Root, T. M. Roberts, T. Golub, K. T. Flaherty, R. Dummer, B. L. Weber, W. R. Sellers, R. Schlegel, J. A. Wargo, W. C. Hahn, L. A. Garraway, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
14. J. Villanueva, A. Vultur, J. T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, A. K. Cipolla, B. Wubbenhorst, X. Xu, P. A. Gimotty, D. Kee, A. E. Santiago-Walker, R. Letrero, K. D'Andrea, A. Pushparajan, J. E. Hayden, K. D. Brown, S. Laquerre, G. A. McArthur, J. A. Sosman, K. L. Nathanson, M. Herlyn, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695 (2010).
15. R. Nazarian, H. Shi, Q. Wang, X. Kong, R. C. Koya, H. Lee, Z. Chen, M. K. Lee, N. Attar, H. Sazegar, T. Chodon, S. F. Nelson, G. McArthur, J. A. Sosman, A. Ribas, R. S. Lo, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
16. C. C. Jiang, F. Lai, K. H. Tay, A. Croft, H. Rizos, T. M. Becker, F. Yang, H. Liu, R. F. Thorne, P. Hersey, X. D. Zhang, Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 1, e69 (2010).
17. K. H. Paraiso, Y. Xiang, V. W. Rebecca, E. V. Abel, Y. A. Chen, A. C. Munko, E. Wood, I. V. Fedorenko, V. K. Sondak, A. R. Anderson, A. Ribas, M. D. Palma, K. L. Nathanson, J. M. Koomen, J. L. Messina, K. S. Smalley, PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760 (2011).
18. H. Puthalakath, L. A. O'Reilly, P. Gunn, L. Lee, P. N. Kelly, N. D. Huntington, P. D. Hughes, E. M. Michalak, J. McKimm-Breschkin, N. Motoyama, T. Gotoh, S. Akira, P. Bouillet, A. Strasser, ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129, 1337-1349 (2007).
19. K. Zhang, R. J. Kaufman, Signaling the unfolded protein response from the endoplasmic reticulum. J. Biol. Chem. 279, 25935-25938 (2004).
20. M. Schröder, R. J. Kaufman, The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739-789 (2005).
21. A. H. Schönthal, Targeting endoplasmic reticulum stress for cancer therapy. Front. Biosci. (Schol. Ed.) 4, 412-431 (2012).
22. C. Xu, B. Bailly-Maitre, J. C. Reed, Endoplasmic reticulum stress: Cell life and death decisions. J. Clin. Invest. 115, 2656-2664 (2005).
23. M. Boyce, J. Yuan, Cellular response to endoplasmic reticulum stress: A matter of life or death. Cell Death Differ. 13, 363-373 (2006).
24. A. Carracedo, M. Lorente, A. Egia, C. Blázquez, S. García, V. Giroux, C. Malicet, R. Villuendas, M. Gironella, L. González-Feria, M. A. Piris, J. L. Iovanna, M. Guzmán, G. Velasco, The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9, 301-312 (2006).
25. M. Salazar, A. Carracedo, I. J. Salanueva, S. Hernández-Tiedra, M. Lorente, A. Egia, P. Vázquez, C. Blázquez, S. Torres, S. García, J. Nowak, G. M. Fimia, M. Piacentini, F. Cecconi, P. P. Pandolfi, L. González-Feria, J. L. Iovanna, M. Guzmán, P. Boya, G. Velasco, Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 119, 1359-1372 (2009).
26. 2+ store itself may be a major factor in thapsigargin-induced ER stress and apoptosis in PC12 cells. Neurochem. Int. 48, 696-702 (2006).
27. J. Li, A. S. Lee, Stress induction of GRP78/BiP and its role in cancer. Curr. Mol. Med. 6, 45-54 (2006).
28. L. Zhuang, R. A. Scolyer, C. S. Lee, S. W. McCarthy, W. A. Cooper, X. D. Zhang, J. F. Thompson, P. Hersey, Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. Histopathology 54, 462-470 (2009).
29. D. Dong, M. Ni, J. Li, S. Xiong, W. Ye, J. J. Virrey, C.Mao, R. Ye, M.Wang, L. Pen, L. Dubeau, S. Groshen, F. M. Hofman, A. S. Lee, Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgeneinduced mammary tumor development. Cancer Res. 68, 498-505 (2008).
30. J. Krochmann, T. Sinnberg, F. Meier, C. Garbe, C. Busch, Melanoma cells in distinct growth phases retain specific invasive qualities during brain metastasis in vivo. Pigment Cell Melanoma Res. 25, 113-114 (2012).
31. K. H. Paraiso, H. E. Haarberg, E. Wood, V. W. Rebecca, Y. A. Chen, Y. Xiang, A. Ribas, R. S. Lo, J. S. Weber, V. K. Sondak, J. K. John, A. A. Sarnaik, J. M. Koomen, K. S. Smalley, The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin. Cancer Res. 18, 2502-2514 (2012).
32. C. C. Jiang, F. Yang, R. F. Thorne, B. K. Zhu, P. Hersey, X. D. Zhang, Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Neoplasia 11, 436-447 (2009).
33. C. C. Jiang, L. H. Chen, S. Gillespie, Y. F. Wang, K. A. Kiejda, X. D. Zhang, P. Hersey, Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stressinduced apoptosis. Cancer Res. 67, 9750-9761 (2007).
34. M. Rahmani, E. M. Davis, T. R. Crabtree, J. R. Habibi, T. K. Nguyen, P. Dent, S. Grant, The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol. Cell. Biol. 27, 5499-5513 (2007).
35. G. V. Mallo, F. Fiedler, E. L. Calvo, E. M. Ortiz, S. Vasseur, V. Keim, J. Morisset, J. L. Iovanna, Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. J. Biol. Chem. 272, 32360-32369 (1997).
36. A. Hoffmeister, A. Ropolo, S. Vasseur, G. V. Mallo, H. Bodeker, B. Ritz-Laser, G. R. Dressler, M. I. Vaccaro, J. C. Dagorn, S. Moreno, J. L. Iovanna, The HMG-I/Y-related protein p8 binds to p300 and Pax2 trans-activation domain-interacting protein to regulate the trans-activation activity of the Pax2A and Pax2B transcription factors on the glucagon gene promoter. J. Biol. Chem. 277, 22314-22319 (2002).
37. U. R. Chowdhury, R. S. Samant, O. Fodstad, L. A. Shevde, Emerging role of nuclear protein 1 (NUPR1) in cancer biology. Cancer Metastasis Rev. 28, 225-232 (2009).
38. C. Malicet, N. Lesavre, S. Vasseur, J. L. Iovanna, p8 inhibits the growth of human pancreatic cancer cells and its expression is induced through pathways involved in growth inhibition and repressed by factors promoting cell growth. Mol. Cancer 2, 37 (2003).
39. J. L. Armstrong, R. Flockhart, G. J. Veal, P. E. Lovat, C. P. Redfern, Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J. Biol. Chem. 285, 6091-6100 (2010).
40. Y. F. Wang, C. C. Jiang, K. A. Kiejda, S. Gillespie, X. D. Zhang, P. Hersey, Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin. Cancer Res. 13, 4934-4942 (2007).
41. P. Hersey, X. D. Zhang, Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell Melanoma Res. 21, 358-367 (2008).
42. H. G. Wendel, E. De Stanchina, J. S. Fridman, A. Malina, S. Ray, S. Kogan, C. Cordon-Cardo, J. Pelletier, S. W. Lowe, Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332-337 (2004).
43. P. Hu, Z. Han, A. D. Couvillon, J. H. Exton, Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J. Biol. Chem. 279, 49420-49429 (2004).
44. K. G. Lasithiotakis, T. W. Sinnberg, B. Schittek, K. T. Flaherty, D. Kulms, E. Maczey, C. Garbe, F. E. Meier, Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol. 128, 2013-2023 (2008).
45. M. L. Mancianti, M. Herlyn, D. Weil, J. Jambrosic, U. Rodeck, D. Becker, L. Diamond, W. H. Clark, H. Koprowski, Growth and phenotypic characteristics of human nevus cells in culture. J. Invest. Dermatol. 90, 134-141 (1988).
46. F. Meier, M. Nesbit, M. Y. Hsu, B. Martin, P. Van Belle, D. E. Elder, G. Schaumburg-Lever, C. Garbe, T. M. Walz, P. Donatien, T. M. Crombleholme, M. Herlyn, Human melanoma progression in skin reconstructs: Biological significance of bFGF. Am. J. Pathol. 156, 193-200 (2000).
47. T. Sinnberg, M. Menzel, D. Ewerth, B. Sauer, M. Schwarz, M. Schaller, C. Garbe, B. Schittek, b-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One 6, e23429 (2011).